Pioneering work by James Allison led to the development of ipilimumab [1, 2], a fully human monoclonal antibody against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which was approved by the FDA in 2011 for the treatment of patients with advanced melanoma. Here, CTLA4 is linked to melanoma.